NASDAQ:PTGX - Protagonist Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.15 +0.19 (+2.39 %) (As of 01/21/2019 04:00 PM ET)Previous Close$7.96Today's Range$7.90 - $8.5052-Week Range$5.49 - $23.97Volume169,878 shsAverage Volume109,218 shsMarket Capitalization$197.12 millionP/E Ratio-3.90Dividend YieldN/ABeta1.97 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California. Receive PTGX News and Ratings via Email Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTGX Previous Symbol CUSIPN/A Webwww.protagonist-inc.com Phone510-474-0170Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12Price-To-Earnings Trailing P/E Ratio-3.90 Forward P/E Ratio-5.16 P/E GrowthN/A Sales & Book Value Annual Sales$20.06 million Price / Sales9.83 Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / Book1.38Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-36,950,000.00 Net Margins-70.54% Return on Equity-24.08% Return on Assets-18.76%Miscellaneous Employees55 Outstanding Shares24,190,000Market Cap$197.12 million OptionableNot Optionable Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions What is Protagonist Therapeutics' stock symbol? Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX." How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics Inc (NASDAQ:PTGX) released its earnings results on Tuesday, November, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.01. The business had revenue of $6.12 million for the quarter, compared to analyst estimates of $6.35 million. Protagonist Therapeutics had a negative return on equity of 24.08% and a negative net margin of 70.54%. View Protagonist Therapeutics' Earnings History. When is Protagonist Therapeutics' next earnings date? Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Protagonist Therapeutics. What price target have analysts set for PTGX? 5 Wall Street analysts have issued 12-month price targets for Protagonist Therapeutics' shares. Their predictions range from $13.00 to $32.00. On average, they anticipate Protagonist Therapeutics' share price to reach $19.40 in the next year. This suggests a possible upside of 138.0% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics. What is the consensus analysts' recommendation for Protagonist Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics. Has Protagonist Therapeutics been receiving favorable news coverage? Press coverage about PTGX stock has trended very positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protagonist Therapeutics earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Who are some of Protagonist Therapeutics' key competitors? Some companies that are related to Protagonist Therapeutics include Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ImmunoGen (IMGN), Epizyme (EPZM), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), G1 Therapeutics (GTHX), AC Immune (ACIU), Urogen Pharma (URGN), Rocket Pharmaceuticals (RCKT), Intra-Cellular Therapies (ITCI), Dicerna Pharmaceuticals (DRNA), Eagle Pharmaceuticals (EGRX), Revance Therapeutics (RVNC) and Omeros (OMER). Who are Protagonist Therapeutics' key executives? Protagonist Therapeutics' management team includes the folowing people: Dr. Dinesh V. Patel, CEO, Pres, Sec. & Director (Age 61)Dr. Richard S. Shames, Chief Medical Officer (Age 58)Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 68)Mr. Thomas P. O'Neil, Chief Financial Officer (Age 53)Dr. Mark Smythe, VP of Technology (Age 53) When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. How do I buy shares of Protagonist Therapeutics? Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Protagonist Therapeutics' stock price today? One share of PTGX stock can currently be purchased for approximately $8.15. How big of a company is Protagonist Therapeutics? Protagonist Therapeutics has a market capitalization of $197.12 million and generates $20.06 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Protagonist Therapeutics employs 55 workers across the globe. What is Protagonist Therapeutics' official website? The official website for Protagonist Therapeutics is http://www.protagonist-inc.com. How can I contact Protagonist Therapeutics? Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected] MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 127 (Vote Outperform)Underperform Votes: 187 (Vote Underperform)Total Votes: 314MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: When is a capital gain realized?